Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003415 · ClinicalTrials.gov registry record · Phase 1
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome
A Phase 1 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00003415 is a Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 26 participants.
The verdict
NCT00003415, a Phase 1 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus topotecan in treating patients with myelodysplastic syndrome.
Interventions
- DRUG topotecan hydrochloride
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 1998-09 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003415
The ClinicalTrials.gov registry entry for NCT00003415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topotecan hydrochloride is the first listed.
NCT00003415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003415 about?
NCT00003415 is a clinical study titled "Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus to...
What is the current status of trial NCT00003415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 1998-09. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00003415?
The interventions under investigation include: topotecan hydrochloride (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003415?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.